Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAGI3 | Q5TCQ9 | 1/20 | 0.55 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.55 |
| ▸ | IL23R | Q5VWK5 | 2/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | GRPR | P30550 | 2/20 | 0.52 |
| ▸ | TLR2 | O60603 | 4/20 | 0.52 |
| ▸ | KISS1R | Q969F8 | 9/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727424 | 0.93 | ERAP2 (0.56) | MAGI3ERAP2IL23RERBB2TLR2 | |
| SCHEMBL29607306 | 0.92 | TLR2 (0.59) | MAGI3IL23RTLR2KISS1R | |
| SCHEMBL30721587 | 0.92 | ERAP2 (0.57) | MAGI3ERAP2IL23RKISS1R | |
| SCHEMBL30301902 | 0.91 | KISS1R (0.60) | MAGI3IL23RERBB2TLR2KISS1R | |
| SCHEMBL29393516 | 0.90 | ERAP2 (0.56) | ERAP2KISS1R | |
| SCHEMBL28674492 | 0.89 | IL23R (0.58) | MAGI3IL23RERBB2KISS1R | |
| SCHEMBL29549608 | 0.89 | KISS1R (0.57) | MAGI3IL23RERBB2TLR2KISS1R | |
| SCHEMBL29525856 | 0.89 | IL23R (0.58) | MAGI3IL23RERBB2TLR2KISS1R | |
| SCHEMBL12262857 | 0.87 | ERBB2 (0.55) | MAGI3ERAP2IL23RERBB2TLR2 | |
| SCHEMBL29639696 | 0.87 | IL23R (0.55) | MAGI3ERAP2IL23RERBB2TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260042811-A1 | NOVEL PEPTIDE HORMONE ANALOGUES | IP2IPO INNOVATIONS LTD (GB) | 2026-02-12 | — | — | US | disclosed |
| EP-3575314-B1 | GLUCAGON DERIVATIVE | HANMI PHARM IND CO LTD (KR) | 2024-02-14 | — | — | EP | disclosed |
| EP-3406264-B1 | COMPOSITION COMPRISING GLP-1 RECEPTOR AGONIST AND GLUCAGON RECEPTOR AGONIST AND APPLICATION THEREOF | PEGBIO CO LTD (CN) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260042811-A1 | NOVEL PEPTIDE HORMONE ANALOGUES | GLP1R, GPR119, IAPP | MAGI3 3375/4885ERAP2 1770/4885IL23R 818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.